We neither found any difference between the levels of anti-MBP from oligodendrocyte-derived EVs between patients with MS with active disease (13.86 ± 6.01 ng/mL) and those with stable disease (12.47 ± 5.83 ng/mL, p=0.20) (Figure 5C). This evidence concerns the gene MBP and myeloid sarcoma.